Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Breast cancer rates rising among Canadian women in their 20s, 30s and 40s
    29 April 2024

    Breast cancer rates rising among Canadian women in their 20s, 30s and 40s

    Researchers highlights need for immediate shift in public health policy as early detection is key to reducing breast cancer death and complications.
  • USFDA approves Pfizer’s BEQVEZ
    27 April 2024
    USFDA approves Pfizer’s BEQVEZ
    BEQVEZ is a one-time treatment that is designed to enable people living with hemophilia B to produce FIX themselves rather than the current standard of care, which requires regular intravenous infusions of FIX that are often administered multiple times a week or multiple times a month.
  • In-Cosmetics Global Exhibition & Conference 2024 held in Paris
    27 April 2024
    In-Cosmetics Global Exhibition & Conference 2024 held in Paris
    In-cosmetics Global 2024 is an international exhibition for the cosmetic industry. It is the meeting place for innovation and development in the entire cosmetics sector worldwide. In recent years, the cosmetics industry has significantly shifted towards using active and natural ingredients in beauty products. This trend reflects a growing consumer preference for skincare and makeup formulations that enhance appearance and offer tangible benefits for skin health.
  • Use of Acid Reflux Drugs Linked to Higher Risk of Migraine
    26 April 2024
    Use of Acid Reflux Drugs Linked to Higher Risk of Migraine
    People who take acid-reducing drugs may have a higher risk of migraine and other severe headache than people who do not take these medications, according to a study published in the April 24, 2024, online issue of Neurology®Clinical Practice, an official journal of the American Academy of Neurology.
  • CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I trial
    26 April 2024
    CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in phase I trial
    CAR T cell therapy has been a highly successful strategy for recurrent or high-risk leukemias or lymphomas, but challenges remain in using this therapy for solid tumors, said first and corresponding author Dr. Meenakshi Hegde, associate professor of pediatrics – hematology and oncology at Baylor and pediatric oncologist at Texas Children’s Cancer Center.
  • Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
    24 April 2024
    Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
    Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer.
  • Dr. Reddy’s issues voluntary recall of Sapropterin Dihydrochloride Powder
    24 April 2024
    Dr. Reddy’s issues voluntary recall of Sapropterin Dihydrochloride Powder
    Dr. Reddys Lab announced that it is voluntarily recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level due to powder discoloration in some packets leading to decreased potency. The issue was discovered during an accelerated stability test in addition to customer complaints.
  • Glial Hyper-Drive for Triggering Epileptic Seizures
    23 April 2024
    Glial Hyper-Drive for Triggering Epileptic Seizures

    Epilepsy, where patients suffer from unexpected seizures, affects roughly 1% of the population. These seizures often involve repetitive and excessive neuronal firing, with the trigger behind this still poorly understood.

  • Key protein regulates immune response to viruses in mammal cells
    23 April 2024
    Key protein regulates immune response to viruses in mammal cells

    Researchers have revealed the regulatory mechanism of a specific protein that plays a key role in balancing the immune response triggered by viral infections in mammal cells. These findings could help drive the development of antiviral therapies and nucleic acid medicines to treat genetic disorders.

  • Zydus launches Mirabegron Extended-Release Tablets in the US
    22 April 2024
    Zydus launches Mirabegron Extended-Release Tablets in the US
    Zydus Lifesciences launches Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug Administration USFDA to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg. Mirabegron is indicated for the treatment of overactive bladder OAB with symptoms of urge urinary incontinence, urgency and urinary frequency
Subscribe to Pharma News